anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
To meet the first objective, we will use Michie's Theoretical Domains Framework (TDF) to identify and organize CP-relevant behaviours. We will conduct qualitative interviews, guided by the TDF and involving knowledge users from participating sites, to identify barriers and facilitators for change relevant to the proposed CP implementation. Experience from other implementation initiatives will also be used to guide the intervention. An intervention mapping technique will be used to select and organize appropriate strategies to affect behaviour changes. Further input will be sought from knowledge user site partners. The intervention will begin with a site visit to assess readiness for adoption, infrastructure requirements, and ability to implement the pathway.

To meet objective two, we will use a cluster randomized control trial (RCT) design, through measurement of relevant clinical and process outcomes in 16 community EDs in Ontario. Using a balanced incomplete block design, we will study this implementation intervention with two clinical pathways: i) Asthma and ii) Vomiting \& Diarrhea (V\&D). We will recruit and randomize 16 community EDs to receive the intervention for one of the CPs and serve as control for the alternate pathway. Primary clinical outcomes for each CP include the following: i) Asthma: the proportion of asthmatic patients with moderate to severe exacerbation who received steroids within 60 minutes from ED presentation; and ii) V\&D: the proportion of children with mild to moderate dehydration treated with oral rehydration therapy. The primary process outcome measure will be the presence of an appropriately completed CP, as per pre-defined criteria, on the chart for relevant patients. Secondary clinical outcomes include disease-specific treatments, ED length of stay, revisits and hospitalizations. Secondary process outcomes include CP use based on shift-level data relating to the busyness of the ED. A mixed methods evaluation will be used to assess clinical and process outcomes. Data sources include chart audits, administrative databases, environmental scans and knowledge user interviews. Sample size calculations for the primary process outcome yielded the highest number of required charts. A total sample size of 6400 patient charts is required to detect an absolute difference of 12% between control and intervention hospitals using a two-sided test at the 5% level of significance.

To meet objective three, a process log will be used to track progress with site deadline targets, implementation issues, degree of uptake, local adaptations and adherence.

And finally, to meet objective four, comparisons of CP implementation and health care costs will be done for all patients with Asthma or V\&D in the pre and post implementation phases at all sites. Additional costs and outcomes will be synthesized in an incremental cost-effectiveness ratio (ICER) comparing intervention and control sites. Cost-effectiveness analyses (CEAs) will be done to relate ICERs to the primary clinical outcome for each CP.
The present invention relates to the technical field of medicine, which particularly relates to a pyrithioxin dihydrochloride freeze-dried composition and a preparation method thereof. The pyrithioxin dihydrochloride freeze-dried composition comprises pyrithioxin dihydrochloride and auxiliary materials, wherein the weight proportion of the pyrithioxin dihydrochloride to the auxiliary materials is 1:0.2 to 2; the auxiliary materials comprise excipient. The preparation method comprises: the pyrithioxin dihydrochloride and the auxiliary materials are put into a material compounding barrel; water for injection is added to the pyrithioxin dihydrochloride and the auxiliary materials; the pyrithioxin dihydrochloride and the auxiliary materials are sufficiently dissolved; active carbon is added to the pyrithioxin dihydrochloride and the auxiliary materials, and is stirred, statically stood and filtered; the filtered solution is then put into a freeze drier to be frozen and dried; after the solution is frozen and dried, the solution is sealed, and the pyrithioxin dihydrochloride freeze-dried composition is obtained. The pyrithioxin dihydrochloride freeze-dried composition of the present invention solves the problem of poor water solubility of pyrithioxin in the prior art, and adopts freeze-dried technology. Moreover, the excipient is added to the pyrithioxin dihydrochloride freeze-dried composition, and the dissolvability of the pyrithioxin is increased. The pyrithioxin dihydrochloride freeze-dried composition solves the problem of poor bioavailability of pyrithioxin.
It has been 40 years since the first IVF baby born in the world. The effects of hormonal drugs used on women and health of IVF offspring have always been concerned in the reproductive field and in public. With the increase of the prevalence of infertility and development of ART, China is facing a IVF babies boom. It has been reported that ART was associated with higher risk of cancers among women undergoing treatment of ART, and an increased incidence of autism and noncommunicable chronic diseases, such as obesity, among IVF offspring. Epigenetics is documented as one of the possible mechanisms, while answers remain to be explored. A birth cohort would provide an opportunity to examine the short- and long-term effects of ART exposure on health consequences of the mothers and babies.
SCALP TREATMENT COMPOSITION                  ABSTRACT OF THE DISCLOSURE      A scalp treatment composition which promotes scalp and hair health and growth was developed in China and approved by medical authorities of the Peoples Republic of China. The com-position consists essentially of ginger, saffron, root bark of shaggy-fruited dittany, the roots of red-rooted salvia, cypress leaves, xiang tong (cinnamornum camphora (linn) sieb.)  , Chin-ese angelica, Sichuan chili, bezoar, artemisia argyi or Chinese mugworth, royal jelly, the dried rhizome of rehmannia, bear's gallbladder, lard, dragon's blood, gypsum, loess, radix, salt, tuber of multiflower knotweed, Chuan poshi (cudrania cochino-hinensis (lour) kudo et masam), blended together in a skin per-meating agent, e.g., cudrania trienspidata (carr) bur. Through survey and clinical observation, it was found that the effect-iveness of this composition to various alopecia reaches 96.82% and to hair loss caused by adipose ooze, 89.82%. The composi-tion is non-poisonous, non harmful and has no side-effect. This composition was the first to pass the inspection of the Chinese Cosmetic Inspection Law since its enactment.
PURPOSE: Patients with colorectal peritoneal metastases (PM) treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are at high risk of recurrent disease. Understanding where and why recurrences occur is the first step in finding solutions to reduce recurrence rates. Although diffusion-weighted (DW) MRI is not routinely used in the follow-up of CRC patients, it has a clear advantage over CT in detecting the location and spread of (recurrent) PM. This study aimed to identify common locations of recurrence in CRC patients after CRS-HIPEC with MRI.
METHOD: This was a single-centre retrospective study of patients with recurrent PM after CRS-HIPEC performed between January 2016 and August 2020. Patients were eligible for inclusion if they had both an MRI preoperatively (MRI1) and at the time of recurrent disease (MRI2). Two abdominal radiologists reviewed in consensus and categorized recurrences according to their location on MRI2 and in correlation with previous disease location on prior imaging (MRI1) and the surgical report of the CRS-HIPEC.
RESULTS: Thirty patients were included, with a median surgical PCI of 7 (range 3-21) at the time of primary CRS-HIPEC. In total, 68 recurrent metastases were detected on MRI2, of which 14 were extra-peritoneal. Of the remaining 54 PM, 42 (78%) occurred where the peritoneum was damaged due to earlier resections or other surgical procedures (e.g. inserted surgical abdominal drains). Most recurrent metastases were found in the mesentery, lower abdomen/pelvis and abdominal wall (87%).
CONCLUSIONS: Most recurrent PMs appeared in the mesentery, lower abdomen/pelvis and abdominal wall, especially where the peritoneum was previously damaged.
Abiraterone inhibits the CYP17A enzyme, which is a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in metastatic castration-resistant prostate cancer (mCRPC) in both chemotherapy-naïve and in the post-docetaxel setting based upon results from two randomized phase III studies. Abiraterone is also proven to extend survival in the metastatic, hormone-naïve population based on two phase III studies. Abiraterone is a castrating agent, but, other than a small first in human study, all clinical studies have been done in conjunction with gonadotropin-releasing hormone (GnRH) analogues. Maintaining castrate level of serum testosterone is critical in the treatment of metastatic prostate cancer. It is unknown if GnRH analogues must be continued to maintain castrate levels of serum testosterone in patients treated with abiraterone.
PURPOSE:To obtain the titled composition having improved bioavailability by oral administration and enabling sure remedy of various diseases caused by the cerebral blood flow disorder, by dissolving cinnarizine in a fatty acid which is liquid at normal temperature. CONSTITUTION:The objective cinnarizine-containing composition for oral administration contains cinnarizine (chemical name: trans-1-cinnamyl-4- diphenylmethylpiperazine) in a state dissolved in a 8-18C fatty acid which is liquid at normal temperature (10-30 deg.C) (e.g. oleic acid, linoleic acid, etc.). The bioavailability can be improved remarkably compared with the solid cinnarizine agent for oral administration. The symptoms such as dizziness, headache, paralysis, etc., caused by the cerebral blood flow disorder such as cerebral apoplexy, cerebral arteriosclerosis, etc., can be surely improved. The titled composition is administered as an oil solution for oral administration, or a soft capsule or hard capsule, etc., filled with the solution.
FIELD: biotechnology.SUBSTANCE: invention relates to medicine, in particular to biotechnology, and can be used to obtain a biosafe culture of mesenchymal stem cells from gelatin of Wharton of human umbilical cord. This method includes isolation of primary culture of mesenchymal stem cells from gelatin of Wharton of umbilical cord tissue after cesarean section. Moreover, during the release of mesenchymal stem cells, the umbilical cord is freed from blood residues and washed in Versene solution with the addition of 100 U/ml of penicillin antibiotics, 100 mcg/ml of streptomycin, 0.25 mcg/ml of amphotericin for 1 hour at room temperature on a shaker, veins are cannulated from both sides and washed with saline (0.9 %). Disaggregation of the tissue is carried out with a solution containing 0.1 % collagenase type 2 and 0.15 % collagenase type 4 prepared in DMEM/F12 at a ratio of 1:1, incubated at 37 °C for 30 min, the separated cells are collected. It is further centrifuged at 800 rpm for 15 minutes to obtain a precipitate of cells, which is resuspended in DMEM/F12 growth medium containing 10 % fetal bovine serum, 100 U/ml of penicillin, 100 mcg/ml of streptomycin, 2 mM of glutamine, 1 mM of sodium pyruvate. Then, the precipitate of cells is resuspended in DMEM/F12 growth medium at a 1:1 ratio, transferred to culture flasks and cultured in atmosphere containing 5 % CObefore the formation of 3/4 monolayer, changing the growth medium 3 times a week. When reaching 3/4 of the monolayer, the cells are subcultured, obtaining the MSC culture, and after 1 passage, a part of the cells is used to detect the presence of AIDS, hepatitis B and C viruses and mycoplasma in the culture by PCR and in the case of a positive result of the test to detect these infections the culture is rejected.EFFECT: use of this method allows to increase the yield and viability of mesenchymal stem cells obtained from gelatin of Wharton of human umbilical cord.1 cl, 1 tbl
BACKGROUND: Temporomandibular disorders (TMDs) are a frequent cause of orofacial pain, causing functional disability and a negative impact on quality of life. Botulinum toxin (BTX-A) injection in lateral pterygoid muscle (LPM) is one of the treatment modalities proposed, but the blind puncture guided by EMG carries a risk of vascular puncture or diffusion of the toxin to nearby muscles. We describe an ultrasound-guided approach and evaluate the spread of the injection in a fresh human cadaver.
METHODS: A fresh human cadaver was injected. An out-of-plane approach was performed using a convex probe, injecting 1.0 ml of 0.25% methylene blue dye into the LPM. After, a dissection was performed to isolate the lateral pterygoid muscle and assess the spread of the dye.
RESULTS: Ultrasound-guided injection allowed to visualize in real-time the spread of the dye within the LPM. The deep and superficial muscles nearby to LPM were not stained by the dye, but upper and lower head of LPM was heavily stained.
CONCLUSION: Ultrasound-guided approach for the injection of BTX-A into the LPM could be considered a successful and safe treatment for myofascial pain related to TMD. Therefore, further clinical studies are needed to study the reproducibility of ultrasound guided LPM injection and to evaluate the clinical results.
This study will be a randomized controlled trial and total sample size of both groups will be 18 and calculated through non-probability sampling technique and the players will allocate into two groups, control group and experimental group, per group sample size is 9. Each will perform the session for occlusion training. Before and after training sessions players completed a series of test to assess their speed and physical performance. Occlusion training will help us providing unique beneficial training mode for promoting muscle hypertrophy. In control group players will perform general exercises session and in experimental sessions players will perform with occlusion training which is blood flow resistance training (BFR training shoulder, leg extension, bicep curls, kaatsu) 4 times a week for 4 weeks with 5 sets of 5 repetitions and then assessed pre-training and post-training values with assessment tools bench press, leg squat, leg power, maximum sprint time and pull-ups performed at 70% of 1-repetition maximum. This training will also improve and increase muscular strength in players.
The invention provides a preparation method of homogeneous traditional Chinese medicinal material raw materials. By using the obtained homogeneous traditional Chinese medicinal material raw materials, the problems of quality difference and the like caused as Chinese patent medicine raw materials or traditional Chinese medicinal decoction pieces have various existential forms, different sizes, uneven thicknesses and different processing approaches are solved. The preparation method comprises the following steps: enacting a content standard for active ingredients of each homogeneous traditional Chinese medicinal material raw material; respectively washing, drying and crushing the traditional Chinese medicinal material raw materials into powder, agitating and mixing the powder evenly, detecting the relevant active ingredients and the contents of the relevant active ingredients, giving a composition formula of the homogeneous traditional Chinese medicinal material raw materials, evenly mixing the powder of the traditional Chinese medicinal material raw materials with different sources according to the formula, detecting the powder again and packing the powder; or making the powder into a normative shape. Therefore, traditional Chinese medicinal materials are more favorably packed uniformly, and are convenient to store, transport and carry, and the quality guarantee period of traditional Chinese medicines is prolonged. The relevant ingredients contained in the obtained homogeneous traditional Chinese medicinal material raw materials and the contents of the relevant ingredients have accurate technical data and are controlled in a determined range. Thus, the relative stability of the quality of the traditional Chinese medicinal material raw materials is guaranteed.
Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction.

Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities.

Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria.

Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated.

Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS).

When these measures are inadequate to control recurrent stone formation, penicillamine capsules may be used as additional therapy, and when patients refuse to adhere to conventional treatment, penicillamine capsules may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients.

Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillamine-cysteine mixed disulfide as:

In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange.
Participants in this group will take part in the 8 sessions of dog-assisted therapy. They will be assessed before and after the 8 week program.
A retrospective analysis of disease histories for the period from 2014 to 2021 was carried out. Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury. In all patients, the assessment of anesthetic risk was carried out according to the ASA scale. The basic tool for pain intensity research was a visual analog scale. Intervals between analgesia were also studied. The study of the neuropathic component of pain was carried out using the Didier Bouhassiraa neuropathic pain diagnostic questionnaire. Study of the presence of an acute stress reaction scale The Hospital Anxiety and Depression Scale. Research on the presence of post-traumatic stress disorders was carried out using the Mississippi scale of post-traumatic stress disorders (military version). Satisfaction with treatment results was studied using the Chaban Quality of Life Scale.
Glanzmann thrombasthenia is a rare bleeding disorder induced by inherited defects of the platelet membrane αIIbβ3 glycoprotein. Glomangiopericytoma, on the other hand, is a very rare sinonasal tumor demonstrating a perivascular myoid phenotype. We herein report the first described case in the literature of Glanzmann thrombasthenia and glomangiopericytoma. The patient is a 40-year-old man diagnosed with type 1 Glanzmann thrombasthenia who presented with repetitive and profuse posterior epistaxis initially managed with platelet transfusions and recombinant activated factor VII (rFVIIa). Due to the unresolved epistaxis, nasal endoscopy was performed revealing a vascularized tumor. Subsequently, a sphenopalatine artery embolization followed by a surgical excision of the tumor was performed. The pathology report diagnosis of the tumor was glomangiopericytoma. This case sheds the lights on a very rare cause of epistaxis in a patient with Glanzmann thrombasthenia, with a challenging multidisciplinary management. A local cause of epistaxis should always be considered even in case of a diagnosed bleeding disorder, especially when the bleeding is recurrent.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of fluocinonide cream because of severe immunosuppression induced in a 13-week dermal rat study. The effects of fluocinonide on fertility have not been evaluated.

Fluocinonide revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames test and chromosomal aberration assay using human lymphocytes). However, fluocinonide was positive for clastogenic potential when tested in the in vivo mouse micronucleus assay.

Topical (dermal) application of 0.0003%-0.03% fluocinonide cream to rats once daily for 13 weeks resulted in a toxicity profile generally associated with long term exposure to corticosteroids including decreased skin thickness, adrenal atrophy, and severe immunosuppression. A NOAEL could not be determined in this study. In addition, topical (dermal) application of 0.1% fluocinonide cream plus UVR exposure to hairless mice for 13 weeks and 150-900 mg/kg/day of 0.1% fluocinonide cream to minipigs (a model which more closely approximates human skin) for 13 weeks produced glucocorticoid-related suppression of the HPA axis, with some signs of immunosuppression noted in the dermal minipig study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk for carcinogenesis.

Topical doses of 0% (fluocinonide cream vehicle), 0.0001%, 0.005% and 0.001% fluocinonide cream were evaluated in a 52 week dermal photo-carcinogenicity study (40 weeks of treatment followed by 12 weeks of observation) conducted in hairless albino mice with concurrent exposure to low level ultraviolet radiation. Topical treatment with increasing concentrations of fluocinonide cream did not have an adverse effect in this study. The results of this study suggest that topical treatment with fluocinonide cream would not enhance photo-carcinogenesis.
Single center, prospective, medical device usability and feasibility study. The study will be performed in Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.

According to the recomandations of the Italian Ministry of Health (28) regarding the sample size of pilot and feasibility studies, 15 applications underwent to mucosal or submucosal resection procedures will be evaluated. The recruitment period will be 36 weeks (9 months). The evaluation ends when ENDONEB has been used in the fifteenth subject or at one third of applications if the investigators will be able to give their evaluation of the feasibility of the ENDONEB technique, usability and safety. The ENDONEB medical device belongs to the family of "Nebulizers" class IIa accessory devices, used to apply Glubran®2 in nebulized form in laparotomic, laparoscopic and thoracoscopic procedures. The ENDONEB medical device allows to apply the Glubran®2 in nebulized form in digestive endoscopy interventions and can be used both with gastroscopes and colonoscopes with an operating channel not less than 2.6 mm. It is marketed in sterile presentation; the components are latex free and is for single use only.